Nissui. has filed a patent for a composition for external skin use containing dihomo-gamma-linolenic acid (DGLA) to treat inflammatory diseases. The method involves administering DGLA topically to the skin. The composition aims to provide anti-inflammatory and antiallergic benefits while ensuring safety. GlobalData’s report on Nissui gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nissui, Nanoemulsion cosmetics was a key innovation area identified from patents. Nissui's grant share as of January 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Composition for external skin use with dihomo-gamma-linolenic acid for inflammation
A recently filed patent (Publication Number: US20240033241A1) outlines a method for treating inflammatory diseases by topically administering dihomo-?-linolenic acid (DGLA) to the skin of a patient. The patent claims specify that the DGLA can be in various forms such as glycerides, phospholipids, glycolipids, alkyl esters, salts, or free fatty acids, with the glyceride form including triglycerides, diglycerides, or monoglycerides. The method involves applying a composition containing 0.01 to 50 wt % of DGLA continuously for at least 7 consecutive days to the affected area, with specific concentrations ranging from 0.05 to 10 wt % in some instances.
Furthermore, the patent claims highlight that the inflammatory disease targeted by this method is primarily inflammatory skin diseases like atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, psoriasis, rheumatism, or lupus. The application of the DGLA composition is aimed at suppressing the itch associated with these conditions. The method allows for flexibility in the concentration of DGLA used and the duration of application, ranging from 7 to 14 consecutive days, depending on the severity of the inflammatory disease. This patent presents a novel approach to managing inflammatory skin diseases by utilizing DGLA in various forms and concentrations, offering potential benefits for patients in need of effective treatment options.
To know more about GlobalData’s detailed insights on Nissui, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
